06/06/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Hepatobiliary Cancers

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Hepatobiliary Cancers. These NCCN Guidelines^® are currently available as Version 2.2017. 

• Hepatocellular Carcinoma
  • For patients with unresectable disease who are not candidates for transplant, regorafenib following progression on or after sorafenib (Child-Pugh Class A only) was changed from category 2B to a category 1 designation. (HCC-5)
  • Regorafenib following progression on or after sorafenib (Child-Pugh Class A only) (HCC-6)
    • This option was changed from category 2B to a category 1 designation in patients with HCC that is inoperable by performance status or comorbidity, local disease or disease with minimal extrahepatic disease only.
    • This option was changed from category 2A to a category 1 designation in patients with metastatic disease or extensive liver tumor burden.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.